hta_admin | Health Technology Assessment Division

[Department Circular No. 2023-0059] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Deferasirox 90 mg and 180 mg Film-Coated Tablet (FCT) for Chronic Iron Overload due to Repetitive Blood Transfusions in Patients 2 Years Old and Above in the Philippine National Formulary (PNF)

Posted on February 13, 2023

[Department Circular No. 2023-0061] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe for the Treatment of Neutropenia in Patients Undergoing Bone Marrow Transplantation and Patients Receiving Myelosuppressive Cancer Chemotherapy in the Philippine National Formulary (PNF)

Posted on February 13, 2023

[DC No. 2023-0060] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe for the Management of Chemotherapy-Induced Anemia in Patients with Non-Myeloid Disease in the Philippine National Formulary (PNF)

Posted on February 13, 2023

Evidence brief for 24 to 31 December 2022

Posted on February 13, 2023

HTAC recommendation on Moderna COVID-19 Vaccine for children 6 to 11 years old

Posted on January 30, 2023

(Update as of 25 January 2023) On 31 August 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC)’s non-recommendation of additional procurement of Moderna for the implementation of the current primary vaccination series for children aged 6 to 11 years old because of its higher cost relative to a similar product in the market. However, existing continue reading : HTAC recommendation on Moderna COVID-19 Vaccine for children 6 to 11 years old